Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Incyte Corporation (INCY) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 24,852,488
  • Shares Outstanding, K 189,410
  • Annual Sales, $ 1,106 M
  • Annual Income, $ 104 M
  • 36-Month Beta 0.78
  • Price/Sales 20.89
  • Price/Cash Flow 130.47
  • Price/Book 54.77

Price Performance

See More
Period Period Low Period High Performance
1-Month
117.10 +12.05%
on 01/31/17
131.89 -0.52%
on 02/24/17
+12.91 (+10.91%)
since 01/24/17
3-Month
98.49 +33.22%
on 12/02/16
131.89 -0.52%
on 02/24/17
+24.41 (+22.86%)
since 11/23/16
52-Week
60.30 +117.60%
on 03/17/16
131.89 -0.52%
on 02/24/17
+56.89 (+76.55%)
since 02/24/16

Most Recent Stories

More News
Picking Up Where We Left Off

Picking Up Where We Left Off

CC : 34.08 (+0.03%)
RLGT : 5.59 (+1.64%)
PPC : 20.43 (-1.07%)
SFLY : 45.95 (-1.69%)
AEM : 45.32 (-0.13%)
QABA : 53.37 (-0.71%)
GOGL : 6.38 (-4.06%)
TSN : 62.68 (-0.22%)
HLT : 57.78 (+1.00%)
FSLR : 37.90 (+1.91%)
CENX : 13.49 (-0.66%)
LPX : 23.39 (-2.50%)
RSX : 20.73 (-1.99%)
STX : 47.75 (+0.76%)
XPO : 50.40 (+1.00%)
AMC : 31.40 (+0.16%)
INCY : 131.21 (+7.59%)
PAK : 17.68 (-0.34%)
TTMI : 16.52 (+0.67%)
CHTR : 326.75 (+0.72%)
PAYC : 55.30 (+2.29%)
What's Driving Lilly's (LLY) Shares after 2016 Decline?

After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.

MRK : 66.16 (+0.47%)
LLY : 82.87 (+0.39%)
INCY : 131.21 (+7.59%)
TEVA : 35.38 (-1.23%)
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook

Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.

MRK : 66.16 (+0.47%)
LLY : 82.87 (+0.39%)
INCY : 131.21 (+7.59%)
NVS : 77.28 (-0.22%)
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

CELG : 118.23 (-1.03%)
INCY : 131.21 (+7.59%)
GILD : 69.94 (+0.82%)
ACOR : 24.90 (-0.40%)
SGEN : 62.73 (-0.54%)
REGN : 361.01 (+0.01%)
BIIB : 285.13 (+0.13%)
Banks Loved Yellen's Testimony

Banks Loved Yellen's Testimony

LVLT : 57.61 (-0.29%)
WY : 33.47 (-0.56%)
CAT : 95.48 (-0.07%)
NEM : 36.08 (+0.61%)
FN : 45.24 (-2.01%)
GRPN : 4.47 (+1.13%)
INCY : 131.21 (+7.59%)
GOGL : 6.38 (-4.06%)
PAYC : 55.30 (+2.29%)
Lilly's Olumiant Gets Marketing Authorization in Europe

Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.

AZN : 29.35 (-0.54%)
LLY : 82.87 (+0.39%)
INCY : 131.21 (+7.59%)
GSK : 41.56 (+0.17%)
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

AXON : 11.72 (-1.01%)
INCY : 131.21 (+7.59%)
PRTA : 53.45 (-1.67%)
ACOR : 24.90 (-0.40%)
Incyte and Agenus Amend Collaboration Agreement

--Agenus to receive $80 million from Incyte: $60 million equity investment at $6 per share and $20 million in accelerated clinical development milestones

AGEN : 3.85 (+0.52%)
INCY : 131.21 (+7.59%)
Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs

--Multiple pivotal programs expected to commence this year, including the combination of epacadostat and pembrolizumab in four additional solid tumor indications

INCY : 131.21 (+7.59%)
What's in Store for Avis Budget (CAR) this Earnings Season?

Avis Budget Group Inc. (CAR) is scheduled to report fourth-quarter 2016 results after market closes on Feb 15.

CCS : 22.80 (+0.22%)
CW : 97.83 (+0.20%)
CAR : 32.46 (-2.81%)
INCY : 131.21 (+7.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of...

See More

Support & Resistance

2nd Resistance Point 134.55
1st Resistance Point 132.88
Last Price 131.21
1st Support Level 128.55
2nd Support Level 125.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.